Latest Insider Transactions at Constellation Pharmaceuticals Inc (CNST)
This section provides a real-time view of insider transactions for Constellation Pharmaceuticals Inc (CNST). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CONSTELLATION PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CONSTELLATION PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 15
2021
|
James E Audia |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,434
-100.0%
|
-
|
|
Jul 15
2021
|
Mark A Goldsmith |
SELL
Sale (or disposition) back to the issuer
|
Direct |
89,857
-100.0%
|
-
|
|
Jul 15
2021
|
Jigar Raythatha |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,961
-100.0%
|
-
|
|
Mar 04
2021
|
Mark A Goldsmith |
BUY
Exercise of conversion of derivative security
|
Direct |
14,987
+50.0%
|
-
|
|
Feb 22
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
6,260
-100.0%
|
$231,620
$37.6 P/Share
|
|
Feb 22
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,260
+50.0%
|
$50,080
$8.04 P/Share
|
|
Feb 19
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,010
-100.0%
|
$148,370
$37.71 P/Share
|
|
Feb 19
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+50.0%
|
$32,080
$8.04 P/Share
|
|
Feb 18
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,100
-100.0%
|
$40,700
$37.58 P/Share
|
|
Feb 18
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,100
+50.0%
|
$8,800
$8.04 P/Share
|
|
Feb 17
2021
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
410
-100.0%
|
$15,170
$37.56 P/Share
|
|
Feb 17
2021
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
410
+50.0%
|
$3,280
$8.04 P/Share
|
|
Feb 17
2021
|
Column Group L P > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
20,000
-9.16%
|
$720,000
$36.95 P/Share
|
|
Jan 19
2021
|
Karen Valentine |
SELL
Open market or private sale
|
Direct |
17,203
-55.18%
|
$567,699
$33.96 P/Share
|
|
Jan 19
2021
|
Karen Valentine |
BUY
Exercise of conversion of derivative security
|
Direct |
17,203
+50.0%
|
$189,233
$11.5 P/Share
|
|
Dec 21
2020
|
Mark A Goldsmith |
SELL
Open market or private sale
|
Indirect |
4,020
-2.81%
|
$140,700
$35.02 P/Share
|
|
Dec 21
2020
|
Emma Reeve Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,720
-100.0%
|
$200,200
$35.11 P/Share
|
|
Dec 21
2020
|
Emma Reeve Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,720
+47.13%
|
$40,040
$7.11 P/Share
|
|
Dec 14
2020
|
Column Group L P > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
60,214
+1.15%
|
$60,214
$1.55 P/Share
|
|
Mar 20
2020
|
Column Group L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
5,539
+0.09%
|
$127,397
$23.15 P/Share
|
|
Mar 19
2020
|
Column Group L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
36,135
+0.59%
|
$794,970
$22.38 P/Share
|
|
Nov 12
2019
|
Regents Of The University Of California |
BUY
Open market or private sale
|
Direct |
12,800
+0.6%
|
$409,600
$32.77 P/Share
|
|
Nov 08
2019
|
Regents Of The University Of California |
BUY
Open market or private sale
|
Direct |
1,074,316
+17.33%
|
$32,229,480
$30.35 P/Share
|
|
Oct 03
2019
|
Column Group L P > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
80,000
+33.45%
|
$640,000
$8.5 P/Share
|
|
Oct 03
2019
|
Column Group L P > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,331,764
+18.14%
|
$10,654,112
$8.5 P/Share
|
|
Jul 23
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+19.31%
|
$3,000,000
$15.0 P/Share
|
|
Jul 23
2018
|
Orbimed Advisors LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
635,842
+50.0%
|
-
|
|
Jul 23
2018
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
200,000
+19.31%
|
$3,000,000
$15.0 P/Share
|
|
Jul 23
2018
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
635,843
+50.0%
|
-
|
|
Jul 23
2018
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
504,743
+50.0%
|
-
|
|
Jul 23
2018
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
266,667
+30.33%
|
$4,000,005
$15.0 P/Share
|
|
Jul 23
2018
|
Column Group L P > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
79,155
+50.0%
|
-
|
|
Jul 23
2018
|
Column Group L P > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
4,666,888
+49.94%
|
-
|
|
Jul 23
2018
|
Regents Of The University Of California |
BUY
Open market or private purchase
|
Direct |
133,333
+5.49%
|
$1,999,995
$15.0 P/Share
|
|
Jul 23
2018
|
Regents Of The University Of California |
BUY
Conversion of derivative security
|
Direct |
2,164,073
+50.0%
|
-
|